The “rights” of precision drug development for Alzheimer’s disease

There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple diso...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey, Feldman, Howard H., Scheltens, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717388/
https://www.ncbi.nlm.nih.gov/pubmed/31470905
http://dx.doi.org/10.1186/s13195-019-0529-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717388/
https://www.ncbi.nlm.nih.gov/pubmed/31470905
http://dx.doi.org/10.1186/s13195-019-0529-5

Ejemplares similares